BioNTech Dirección

Dirección controles de criterios 4/4

El CEO de BioNTech's es Ugur Sahin , nombrado en Jan 2008, tiene una permanencia de 16.25 años. compensación anual total es €3.06M, compuesta por 22.9% salario y 77.1% primas, incluidas acciones y opciones de la empresa. posee directamente un 17.14% de las acciones de la empresa, por valor de $3.58B. La antigüedad media del equipo directivo y de la junta directiva es de 5.3 años y 4 años, respectivamente.

Información clave

Ugur Sahin

Chief Executive Officer (CEO)

€3.1m

Compensación total

Porcentaje del salario del CEO	22.9%
Permanencia del CEO	16.3yrs
Participación del CEO	17.1%
Permanencia media de la dirección	5.3yrs
Promedio de permanencia en la Junta Directiva	4yrs

Actualizaciones recientes de la dirección

Recent updates

BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt

Apr 22

We Think You Can Look Beyond BioNTech's (NASDAQ:BNTX) Lackluster Earnings

Mar 27

BioNTech SE Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Mar 24

BioNTech's Brew: Mixing COVID Legacy With Oncology Ambitions

Mar 20

BioNTech Buys Into Autolus' Cell Therapy Tech - Why I Expect A Full Acquisition In Time

Feb 23

BioNTech SE (NASDAQ:BNTX) Shares Could Be 30% Above Their Intrinsic Value Estimate

Feb 09

Growth Investors: Industry Analysts Just Upgraded Their BioNTech SE (NASDAQ:BNTX) Revenue Forecasts By 20%

Jan 18

Bearish: Analysts Just Cut Their BioNTech SE (NASDAQ:BNTX) Revenue and EPS estimates

Feb 02

With EPS Growth And More, BioNTech (NASDAQ:BNTX) Makes An Interesting Case

Jan 26

BioNTech SE (NASDAQ:BNTX) Held Back By Insufficient Growth Even After Shares Climb 36%

Nov 19

BioNTech (NASDAQ:BNTX) Seems To Use Debt Rather Sparingly

Nov 09

CDC advisory panel recommends COVID vaccines for children be included in federal program

Oct 19

Do BioNTech's (NASDAQ:BNTX) Earnings Warrant Your Attention?

Oct 18

Hong Kong approves BioNTech COVID vaccine for infants

Oct 12

EMA starts rolling review of Pfizer/BioNTech's Omicron-subvariant adapted shot for kids

Oct 03

BioNTech: A Tale Of 2 Companies

Sep 20

European drug regulator panel backs approval of Pfizer/BioNTech's Omicron-adapted shot

Sep 12

CDC advisors to vote on COVID Omicron vaccines on Sept. 1

Aug 30

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Ugur Sahin en comparación con los beneficios de BioNTech?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	€3m	€700k	€930m
Sep 30 2023	n/a	n/a	€3b
Jun 30 2023	n/a	n/a	€4b
Mar 31 2023	n/a	n/a	€6b
Dec 31 2022	€6m	€360k	€9b
Sep 30 2022	n/a	n/a	€10b
Jun 30 2022	n/a	n/a	€12b
Mar 31 2022	n/a	n/a	€13b
Dec 31 2021	€12m	€360k	€10b
Sep 30 2021	n/a	n/a	€7b
Jun 30 2021	n/a	n/a	€4b
Mar 31 2021	n/a	n/a	€1b
Dec 31 2020	€17m	€360k	€15m
Sep 30 2020	n/a	n/a	-€410m
Jun 30 2020	n/a	n/a	-€230m
Mar 31 2020	n/a	n/a	-€192m
Dec 31 2019	€7m	€311k	-€179m
Sep 30 2019	n/a	n/a	-€122m
Jun 30 2019	n/a	n/a	-€116m
Mar 31 2019	n/a	n/a	-€77m
Dec 31 2018	€653k	€210k	-€48m

Compensación vs. Mercado: La compensación total de Ugur($USD3.28M) está por debajo de la media de empresas de tamaño similar en el mercado US ($USD13.51M).

Compensación vs. Ingresos: La compensación de Ugur ha sido consistente con los resultados de la empresa en el último año.

CEO

Ugur Sahin (58 yo)

16.3yrs

Permanencia

€3,056,000

Compensación

Prof. Dr. Ugur Sahin, MD, is the Chief Executive Officer and Co-Founder of BioNTech SE since 2008 and serves as its Member of Management Board since 2008 and serves as its Chair of the Management Board. Pr...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Ugur Sahin	Co-Founder	16.3yrs	€3.06m	17.14% € 3.6b
Ozlem Tureci	Co-Founder	6.3yrs	€814.00k	0.38% € 79.6m
Jens Holstein	CFO & Member of Management Board	2.8yrs	€1.32m	0.00067% € 140.8k
Sierk Poetting	MD, COO & Member of Management Board	10.3yrs	€821.00k	0.31% € 65.8m
Ryan Richardson	Chief Strategy Officer	4.3yrs	€1.41m	0.0061% € 1.3m
Sean Marett	Chief Business Officer	12.3yrs	€133.00k	0.34% € 71.1m
James Timothy Ryan	Chief Legal Officer & Member of the Management Board	less than a year	€848.00k	sin datos
Zach Taylor	Senior Vice President of Corporate Development & Strategy	less than a year	sin datos	sin datos
Katalin Kariko	Senior VP & External Consultant for RNA Protein Replacement Therapies	no data	sin datos	sin datos
Oliver Henning	Senior Vice President of Operations	no data	sin datos	sin datos
Sebastian Kreiter	Senior Vice President of Immunotherapy & Preclinical Research	no data	sin datos	sin datos
Siegbert Kloos	Senior Vice President of Global R&D Digital	no data	sin datos	sin datos

5.3yrs

Permanencia media

56yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de BNTX es experimentado (5.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Rudolf Staudigl	Supervisory Board Member	1.8yrs	€90.00k	0.00017% € 35.7k
Ulrich Wandschneider	Independent Deputy Chairman Supervisory Board	6.3yrs	€114.00k	sin datos
Michael Motschmann	Independent Supervisory Board Member	16.3yrs	€80.00k	sin datos
Helmut Jeggle	Independent Supervisory Board Chairman	16.3yrs	€226.00k	0.14% € 29.0m
Nicola Blackwood	Member of Supervisory Board	less than a year	€46.00k	sin datos
Anja Morawietz	Supervisory Board Member	1.8yrs	€105.00k	0.00010% € 21.0k

4.0yrs

Permanencia media

57.5yo

Promedio de edad

Junta con experiencia: La junta directiva de BNTX se considera experimentada (4 años de antigüedad promedio).

BioNTech Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

BioNTech SE Announces Appointment of Annemarie Hanekamp as Chief Commercial Officer, Effective July 1, 2024

BioNTech SE Announces Retirement of Sean Marett as Chief Business and Commercial Officer

BioNTech SE, Annual General Meeting, May 17, 2024

Independent Supervisory Board Chairman notifies of intention to sell stock

BioNTech Appoints James Ryan as Chief Legal Officer Effective September 1, 2023

Independent Supervisory Board Chairman notifies of intention to sell stock

Recent updates

BioNTech SE to Report Q1, 2024 Results on May 06, 2024

BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt

Consensus EPS estimates fall by 11%

We Think You Can Look Beyond BioNTech's (NASDAQ:BNTX) Lackluster Earnings

Consensus EPS estimates have been downgraded.

BioNTech SE Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS and revenues miss analyst expectations

BioNTech SE Announces Appointment of Annemarie Hanekamp as Chief Commercial Officer, Effective July 1, 2024

BioNTech's Brew: Mixing COVID Legacy With Oncology Ambitions

Now 21% undervalued after recent price drop

BioNTech SE Announces Retirement of Sean Marett as Chief Business and Commercial Officer

BioNTech Buys Into Autolus' Cell Therapy Tech - Why I Expect A Full Acquisition In Time

BioNTech SE (NASDAQ:BNTX) Shares Could Be 30% Above Their Intrinsic Value Estimate

BioNTech SE and Duality Biologics (Suzhou) Co., Ltd. Receives FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325 DB-1305

BioNTech SE and Duality Biologics (Suzhou) Co., Ltd. Initiate Pivotal Phase 3 Trial of Antibody-Drug Conjugate Candidate BNT323 DB-1303 in Metastatic Breast Cancer

Growth Investors: Industry Analysts Just Upgraded Their BioNTech SE (NASDAQ:BNTX) Revenue Forecasts By 20%

Robbins LLP Informs Investors of Class Action Filed Against BioNTech SE

Earnings Working Against BioNTech SE's (NASDAQ:BNTX) Share Price

BioNTech and Duality Biologics (Suzhou) Co. Ltd. Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323 DB-1303 in Endometrial Cancer

BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt

BioNTech SE (NasdaqGS:BNTX) agreed to acquire Aexerna Therapeutics.

BioNTech SE to Report Q4, 2023 Results on Mar 20, 2024

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Pfizer Inc. and BioNTech SE Announce Positive Topline Data for MRNA-Based Combination Vaccine Program Against Influenza and Covid-19

Time To Worry? Analysts Are Downgrading Their BioNTech SE (NASDAQ:BNTX) Outlook

BioNTech SE, Annual General Meeting, May 17, 2024

BioNTech SE Expands Late-Stage Clinical Oncology Portfolio with Initiation of Further Phase 2 Trial with mRNA-Based Individualized Neoantigen Specific Immunotherapy in New Cancer Indication

New major risk - Revenue and earnings growth

Consensus EPS estimates fall by 13%

Independent Supervisory Board Chairman notifies of intention to sell stock

Curevac Reports Progress in Intellectual Property Infringement Case Against Biontech in Germany

Pfizer and Biontech Receive Health Canada Authorization for Xbb.1.5-Adapted Monovalent Covid-19 Vaccine

Pfizer Inc. and BioNTech SE Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine

BioNTech (NASDAQ:BNTX) Has A Rock Solid Balance Sheet

Investor sentiment improves as stock rises 17%

BioNTech Appoints James Ryan as Chief Legal Officer Effective September 1, 2023

BioNTech SE to Report Q3, 2023 Results on Nov 06, 2023

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

BioNTech SE acquired remaining stake in InstaDeep Ltd for approximately £430 million.

BioNTech SE to Report Q2, 2023 Results on Aug 07, 2023

Independent Supervisory Board Chairman notifies of intention to sell stock

BioNTech SE and OncoC4, Inc. Initiate Pivotal Phase 3 Trial of BNT316/ONC-392 Program in Metastatic NSCLC

Is BioNTech (NASDAQ:BNTX) A Risky Investment?

Consensus EPS estimates fall by 15%

A Look At The Intrinsic Value Of BioNTech SE (NASDAQ:BNTX)

BioNTech SE Provides Revenue Guidance for the Full Year 2023

Consensus EPS estimates increase by 10%

Consensus EPS estimates fall by 10%

BioNTech SE (NASDAQ:BNTX) Analysts Just Slashed This Year's Estimates

Full year 2022 earnings: EPS and revenues exceed analyst expectations

These 4 Measures Indicate That BioNTech (NASDAQ:BNTX) Is Using Debt Safely

A Look At The Fair Value Of BioNTech SE (NASDAQ:BNTX)

Bearish: Analysts Just Cut Their BioNTech SE (NASDAQ:BNTX) Revenue and EPS estimates

With EPS Growth And More, BioNTech (NASDAQ:BNTX) Makes An Interesting Case

Investor sentiment deteriorated over the past week

BioNTech SE Initiates Phase 1 Clinical Trial for Malaria Vaccine Program BNT165

BioNTech SE Starts Phase 1 Clinical Trial for Prophylactic Herpes Simplex Virus-2 Vaccine Candidate BNT163

Pfizer and BioNTech SE Omicron Ba.4/Ba.5-Adapted Bivalent Covid-19 Vaccine Booster Receives Health Canada Authorization for Children 5 Through <12 Years of Age

BioNTech SE and Pfizer Inc. Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-adapted bivalent COVID-19 Vaccine in Children Under 5 years

Pfizer and BioNTech Report New Data on Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Improved Immune Response Against Emerging Omicron Sublineages

BioNTech SE (NASDAQ:BNTX) Held Back By Insufficient Growth Even After Shares Climb 36%

Pfizer Inc. and BioNTech SE Advances Next-Generation COVID-19 Vaccine Strategy with Study Start of Candidate Aimed at Enhancing Breadth of T Cell Responses and Duration of Protection

Pfizer and Biontech Receive Positive Chmp Opinion for Omicron Ba.4/Ba.5-Adapted Bivalent Covid-19 Vaccine Booster for Children 5 Through 11 Years of Age in European Union

BioNTech (NASDAQ:BNTX) Seems To Use Debt Rather Sparingly

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

BioNTech SE Se Revises Its Earnings Guidance for the Full Year 2022

Pfizer Inc. and BioNTech SE Announces Updated Clinical Data for Omicron Ba.4/Ba.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine

Investor sentiment deteriorated over the past week